Main Menu

Strongbridge Biopharma plc


Rigrodsky Law, P.A. announces that it is investigating Strongbridge Biopharma plc (“Strongbridge”) regarding possible breaches of fiduciary duties and other violations of law related to Strongbridge’s agreement to be acquired by Xeris Pharmaceuticals, Inc.  Under the terms of the agreement, Strongbridge's shareholders will receive 0.7840 shares of Xeris Biopharma Holdings, Inc. plus one contingent value right per share.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 06/12/2021

* Indicates a required field.

Back to Page